SCHEMBL712120

SCHEMBL712120

Nc1ccc(S(=O)(=O)Nc2nccs2)c(F)c1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.62
ALDH1A1 P00352 1/20 0.62
LMNA P02545 1/20 0.62
CYP2C9 P11712 1/20 0.62
EDNRA P25101 1/20 0.62
SLC6A4 P31645 1/20 0.62
ADRA1A P35348 1/20 0.62
PRMT6 Q96LA8 1/20 0.62
TDP1 Q9NUW8 1/20 0.62
SCN9A Q15858 4/20 0.60
SCN3A Q9NY46 1/20 0.53
USP2 O75604 1/20 0.53
MAPT P10636 1/20 0.53
ESR2 Q92731 1/20 0.53
HSD17B10 Q99714 1/20 0.53
SCN1A P35498 13/20 0.52
SCN5A Q14524 13/20 0.52
SCN8A Q9UQD0 13/20 0.52
SCN1B Q07699 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1095178 0.86 SCN9A (0.62) SCN9ASCN3AUSP2MAPTESR2
SCHEMBL712317 0.84 SCN9A (0.60) SCN9ASCN3AUSP2MAPTESR2
SCHEMBL711931 0.82 SCN9A (0.57) SCN9ASCN3AUSP2MAPTESR2
SCHEMBL16177329 0.81 SCN5A (0.59) SCN9AUSP2MAPTESR2HSD17B10
SCHEMBL17774558 0.81 ALDH1A1 (0.62) KDM4EALDH1A1LMNACYP2C9EDNRA
SCHEMBL3123507 0.81 SCN9A (0.59) ALDH1A1SCN9ASCN3AUSP2MAPT
SCHEMBL1094208 0.80 SCN9A (0.61) SCN9AUSP2MAPTESR2HSD17B10
SCHEMBL29668582 0.80 SCN9A (0.61) SCN9AUSP2MAPTESR2HSD17B10
SCHEMBL713272 0.79 SCN9A (0.53) ALDH1A1LMNASCN9AUSP2MAPT
SCHEMBL20095581 0.79 SCN5A (0.59) SCN9AUSP2MAPTESR2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A KDM4E 2087/4885ALDH1A1 3333/4885LMNA 2921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.